Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: A case-control study

Inflammatory Bowel Diseases

Volumn 15, Issue 5, 2009, Pages 772-777

  Hanson, Karen A ^a   Loftus Jr , Edward V ^a   Hármsen, W Scott ^a   Diehl, Nancy N ^a   Zinsmeister, Alan R ^a   Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Case control; Clinical features; IBD; Narcotic use

Indexed keywords

NARCOTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL STRESS; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PHYSICAL STRESS; PRIORITY JOURNAL; SEX DIFFERENCE; SEXUAL ABUSE; SUBSTANCE ABUSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 67650311568     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20847     Document Type: Article

References (11)

1. Edwards JT, Radford-Smith GL, Florin TH. Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics. J Gastroenterol Hepatol. 2001;16:1235-1238.
2. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005;100:2225-2229.
3. Grunkemeier DM, Cassara JE, Dalton CB, et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007;5:1126-1139.
4. Drossman DA. Chronic functional abdominal pain. Am J Gastroenterol. 1996;91:2270-2281.
5. Drossman DA. A biopsychosocial understanding of gastrointestinal illness and disease. In: Feldman, ed. Sleisenger & Fordtran's Gastrointestinal and Liver Disease (7th ed.). St. Louis: WB Saunders; 2002:2373-2385.
6. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
7. Walker EA, Gelfand MD, Gelfand AN, et al. The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. Gen Hosp Psychiatry. 1996;18:215-219.
8. Demco L. Pain mapping of adhesions. J Am Assoc Gynecol Laparosc. 2004;11:181-183.
9. Swank DJ, Jeekel H. Laparoscopic adhesiolysis in patients with chronic abdominal pain. Curr Opin Obstet Gynecol. 2004;16:313-318.
10. Herrick SE, Mutsaers SE, Ozua P, et al. Human peritoneal adhesions are highly cellular, innervated, and vascularized. J Pathol. 2000;192:67-72.
11. Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients with inflammatory bowel disease. Cleve Clin J Med. 1992;59: 35-42.